Latest Headlines

Latest Headlines

Xenon's Teva-partnered pain drug flunks a test in osteoarthritis

Xenon Pharmaceuticals' Teva-partnered treatment for osteoarthritis pain missed its goals in a Phase IIb trial, a failure the biotech believes won't derail the drug's development in other indications.

IPOs: Molecular Partners and Xenon pull off downsized debuts amid a shaky market

Biotechs Molecular Partners and Xenon Pharmaceuticals finally made their way to the public markets after previously postponing their IPOs, but each had to settle for a substantial discount in the process as investors continue to greet drug developers with skepticism.

IPO optimism brings Molecular Partners and Xenon back to the table

Two biotechs are again mounting IPO efforts after market volatility scuttled their first attempts, as Molecular Partners and Xenon Pharmaceuticals pitch downsized offerings in hopes of finally making onto the public markets.

Xenon pitches Genentech, Teva 'extreme genetics' ties as it rolls out a $52M IPO

Xenon Pharmaceuticals has gone 8 long years since its last equity raise, relying on a slate of partnerships with some of the biggest names in the business to fund its work. And now it's set out to test the fall biotech IPO market with a $52 million offering designed to take the company down another stage of its journey through the clinic.

Merck advances two partnerships with biotech Canucks

As Merck works on rebooting R&D, the drug giant has rewarded a pair of its biotech partners in Canada for their progress with separate preclinical programs. This week Xenon and Zymeworks, both headquartered in Vancouver, have reported new developments in their partnerships with Merck.

Genetics-focused Xenon forges $646M pain pact with Genentech

Canada's Xenon has added another premier industry collaboration to its roster of pacts aimed at discovering genetically-targeted treatments. In this new deal, Xenon will work with Roche 's Genentech

Merck inks drug discovery deal with Xenon

Merck has signed a deal with Canada-based Xenon to discover and develop small molecule candidates for cardiovascular disease. Xenon, a clinical genetics-based drug discovery and development outfit,